Original articleSystematic reviews and meta-analysesAdverse Events After Radiofrequency Ablation in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis
Section snippets
Study Selection
We followed the Preferred Reporting Items for Systemic Reviews and Meta-Analysis guidelines for this study.8 A study was included in our analysis if it (1) was a clinical trial, prospective study, or retrospective study; (2) was published in a peer-reviewed journal or a meeting abstract (2012–2014); (3) had patients with BE, with or without dysplasia, who were treated with RFA with or without EMR; and (4) monitored and reported adverse events. A study was excluded if (1) the rate of adverse
Results
Our search resulted in 1521 citations between 1980 and 2014. Of those, 37 studies (28 published manuscripts and 9 meeting abstracts) met the inclusion criteria, totaling 9200 patients.5, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 These included 16 prospective studies/clinical trials (totaling 791 patients) and 21 retrospective studies (totaling 8409 patients). Further details on study selection
Clinical Implications
As the incidence of EAC continues to increase, clinicians need to identify and treat potential risk factors of this deadly disease. BE is one of the major risk factors for EAC. Endoscopic therapy, RFA with or without EMR, to treat BE-related dysplasia has increased dramatically during the past decade. With the spreading use of RFA, clinicians need better understanding of the potential adverse events involved with this treatment method. In this meta-analysis, we showed that the overall risk of
Conclusions
The results of this systematic review and meta-analysis provide estimates of the rate of overall and individual adverse events related to RFA with and without EMR; stricture formation was the most common adverse event. The rate of severe adverse events (perforation) is very low. The use of EMR to remove nodules or lesions, although essential, appears to significantly increase the risk of adverse events. It is critical to discuss these issues with patients before embarking on such treatment
References (50)
- et al.
Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2013) Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus
Clin Gastroenterol Hepatol
(2013)Durability of radiofrequency ablation in Barrett's esophagus with dysplasia
Gastroenterology
(2011)Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia
Clin Gastroenterol Hepatol
(2010)Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus
Clin Gastroenterol Hepatol
(2012)What are the outcomes of endoscopic radiofrequency ablation for very long segments of Barrett esophagus containing neoplasia?
Gastrointest Endosc
(2009)Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry
Gastroenterology
(2013)Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium
Gastroenterology
(2013)Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry
Gastrointest Endosc
(2008)Radiofrequency ablation of Barrett's esophagus: short-term results
Ann Thorac Surg
(2009)
Radiofrequency ablation associated to mucosal resection in the oesophagus: experience in a single centre
Clin Res Hepatol Gastroenterol
Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry
J Gastrointest Surg
Comparison of endoscopic treatment modalities for Barrett's neoplasia
Gastrointest Endosc
Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in barrett's esophagus longer than 7 CM
Gastrointest Endosc
Radiofrequency ablation in the esophagus: results of a prospective multicenter belgian registry
Gastrointest Endosc
Radiofrequency ablation of barrett's esophagus: preliminary outcomes of 80 patients from a multicenter registry in Italy
Dig Liver Dis
Efficacy of radiofrequency ablation in management of barrett's esophagus: real-life experience of two western canadian centers
Gastrointest Endosc
Efficacy, durability and safety of radiofrequency ablation for nondysplastic barrett's esophagus at a university referral center
Gastroenterology
Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study
Gastrointest Endosc
Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase
Clin Gastroenterol Hepatol
Comparison of endoscopic treatment modalities for Barrett's neoplasia
Gastrointest Endosc
Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett's esophagus: a critical assessment of histologic outcomes and adverse events
Gastrointest Endosc
Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia
Gastrointest Endosc
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia
Clin Gastroenterol Hepatol
Trends in esophageal adenocarcinoma incidence and mortality
Cancer
Cited by (133)
Predictive factors of radiofrequency ablation failure in the treatment of dysplastic Barrett's esophagus
2023, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :Two patients with post-procedural chest pain for more than 7 days and one spontaneously resolutive fever episode were recorded. The 12.5% rate of esophageal strictures, higher than the 6% reported by Qumseya et al. [20], could be explained by the high number of RFA treatment sessions, and using ESD in 21% of the patients, leading to more scarring in the esophagus, and to an increased post RFA stricture rate [21]. Among patients who initially reached CE-IM, we recorded a recurrence rate of metaplasia or dysplasia of 38% (n = 22/57) over a median follow-up of 29 months, of which 12 (12/57, 21%) were clinically significant due to the extension of intestinal metaplasia or the presence of dysplasia.
Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma
2022, Gastroenterology Clinics of North AmericaClinical and morphological diagnosis of eosinophilic esophagitis
2023, Clinical and Experimental Morphology
Conflicts of interest These authors disclose the following: Dr Wolfsen receives research funding from Olympus and Ninepoint Medical. Dr Sharma receives research funding from Olympus, Cook, and Takeda. Dr Wani has received educational grants from Covidien, Cook, and Boston Scientific and is a consultant for Covidien. The remaining authors disclose no conflicts.